| Jennifer Binkley Daggett, CRNP | |
|
1000 1st St N, Alabaster, AL 35007-8703 | |
| (205) 620-7004 | |
| Not Available |
| Full Name | Jennifer Binkley Daggett |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 26 Years |
| Location | 1000 1st St N, Alabaster, Alabama |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598825051 | NPI | - | NPPES |
| 891017304 | Medicaid | AL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LA2100X | Nurse Practitioner - Acute Care | 1-110895 (Alabama) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Heart South Cardiovascular Group, P.c. | 3476455668 | 21 |
News Archive
Infinity Pharmaceuticals, Inc. today announced updated data from the Phase 1b portion of an ongoing Phase 1b/2 clinical trial of saridegib in combination with the chemotherapy gemcitabine in patients with previously untreated, metastatic pancreatic cancer.
Resistance of leukemia cells to contemporary chemotherapy is one of the most formidable obstacles to treating acute lymphoblastic leukemia (ALL), the most common form of childhood cancer. Now researchers at Children's Hospital Los Angeles have designed and developed a new protein-based therapy they believe will prove highly effective against drug-resistant leukemia cells.
As an additional measure in the fight against Zika virus, today the U.S. Food and Drug Administration announced that it has made available a panel of human plasma samples to aid in the regulatory evaluation of serological tests to detect recent Zika virus infection.
A two-vaccine regimen intended to protect against Ebola virus disease induced an immune response that persisted for approximately one year in healthy adult volunteers, according to results from a Phase 1 clinical trial published in the March 14th issue of the Journal of the American Medical Association.
› Verified 5 days ago
| Entity Name | Heart South Cardiovascular Group, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588641005 PECOS PAC ID: 3476455668 Enrollment ID: O20040127000578 |
News Archive
Infinity Pharmaceuticals, Inc. today announced updated data from the Phase 1b portion of an ongoing Phase 1b/2 clinical trial of saridegib in combination with the chemotherapy gemcitabine in patients with previously untreated, metastatic pancreatic cancer.
Resistance of leukemia cells to contemporary chemotherapy is one of the most formidable obstacles to treating acute lymphoblastic leukemia (ALL), the most common form of childhood cancer. Now researchers at Children's Hospital Los Angeles have designed and developed a new protein-based therapy they believe will prove highly effective against drug-resistant leukemia cells.
As an additional measure in the fight against Zika virus, today the U.S. Food and Drug Administration announced that it has made available a panel of human plasma samples to aid in the regulatory evaluation of serological tests to detect recent Zika virus infection.
A two-vaccine regimen intended to protect against Ebola virus disease induced an immune response that persisted for approximately one year in healthy adult volunteers, according to results from a Phase 1 clinical trial published in the March 14th issue of the Journal of the American Medical Association.
› Verified 5 days ago
| Entity Name | Baptist Health Centers Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265496236 PECOS PAC ID: 3476457011 Enrollment ID: O20180124001442 |
News Archive
Infinity Pharmaceuticals, Inc. today announced updated data from the Phase 1b portion of an ongoing Phase 1b/2 clinical trial of saridegib in combination with the chemotherapy gemcitabine in patients with previously untreated, metastatic pancreatic cancer.
Resistance of leukemia cells to contemporary chemotherapy is one of the most formidable obstacles to treating acute lymphoblastic leukemia (ALL), the most common form of childhood cancer. Now researchers at Children's Hospital Los Angeles have designed and developed a new protein-based therapy they believe will prove highly effective against drug-resistant leukemia cells.
As an additional measure in the fight against Zika virus, today the U.S. Food and Drug Administration announced that it has made available a panel of human plasma samples to aid in the regulatory evaluation of serological tests to detect recent Zika virus infection.
A two-vaccine regimen intended to protect against Ebola virus disease induced an immune response that persisted for approximately one year in healthy adult volunteers, according to results from a Phase 1 clinical trial published in the March 14th issue of the Journal of the American Medical Association.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jennifer Binkley Daggett, CRNP 1130 22nd St S Ste 1000, Birmingham, AL 35205-2881 Ph: () - | Jennifer Binkley Daggett, CRNP 1000 1st St N, Alabaster, AL 35007-8703 Ph: (205) 620-7004 |
News Archive
Infinity Pharmaceuticals, Inc. today announced updated data from the Phase 1b portion of an ongoing Phase 1b/2 clinical trial of saridegib in combination with the chemotherapy gemcitabine in patients with previously untreated, metastatic pancreatic cancer.
Resistance of leukemia cells to contemporary chemotherapy is one of the most formidable obstacles to treating acute lymphoblastic leukemia (ALL), the most common form of childhood cancer. Now researchers at Children's Hospital Los Angeles have designed and developed a new protein-based therapy they believe will prove highly effective against drug-resistant leukemia cells.
As an additional measure in the fight against Zika virus, today the U.S. Food and Drug Administration announced that it has made available a panel of human plasma samples to aid in the regulatory evaluation of serological tests to detect recent Zika virus infection.
A two-vaccine regimen intended to protect against Ebola virus disease induced an immune response that persisted for approximately one year in healthy adult volunteers, according to results from a Phase 1 clinical trial published in the March 14th issue of the Journal of the American Medical Association.
› Verified 5 days ago
Stephanie Lynn Woods, Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1000 1st St N, Alabaster, AL 35007 Phone: 205-620-7059 | |
Jenifer Justice, CRNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 145 Sundance, Alabaster, AL 35007 Phone: 662-640-8804 | |
Mrs. Amanda T Cabaniss, RN, CRNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1024 1st St N, Central Alabama Oncology, Llc, Alabaster, AL 35007 Phone: 205-664-4051 Fax: 205-664-4054 | |
Brody Weldon, CRNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1000 1st St N, Alabaster, AL 35007 Phone: 205-620-7004 | |
Mr. Ricardo Paitz, ACNPC-AG Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1000 1st St N, Alabaster, AL 35007 Phone: 205-620-8100 | |
Jennifer Gafnea, CRNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 300 1st St N Ste C, Alabaster, AL 35007 Phone: 205-381-2381 | |
William Alexander Woodard, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 300 1st Street North Ste. C, Alabaster, AL 35007 Phone: 205-663-5990 |